Funding for this research was provided by:
Association Vaincre la Mucoviscidose (RF20160501626)
Received: 8 January 2019
Accepted: 14 October 2019
First Online: 27 February 2020
: Pr L. Delhaes is member of the scientific advisory board of “Vaincre la Mucoviscidose”, and of the executive committee of ESGHAMI (ESCMID working group). She also did punctual consulting for pharmaceutical companies (Pfizer, Gilead, and MSD) and was invited to participate to scientific congresses as compensations. The other authors declare no potential conflict of interest.